Healthcare stocks were flat to higher pre-bell Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3%.
ACADIA Pharmaceuticals (ACAD) shares were down more than 4% in premarket activity after the company reported that its phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis narrowly missed its primary endpoint.